New Results from KARDIA-1 Phase 2 Study of Zilebesiran Presented at the American Heart Association (AHA) Scientific Sessions 2023

11 Nov, 2023 New Results from KARDIA-1 Phase 2 Study of Zilebesiran Presented at the American Heart Association (AHA) Scientific Sessions 2023

New results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of patients with hypertension and high cardiovascular risk, were presented at the American Heart Association (AHA) Scientific Sessions 2023.

Bakris, et al. “Sustained Blood Pressure Reduction with the RNA Interference Therapeutic, Zilebesiran: Primary Results from KARDIA-1, a Phase 2 Study in Patients with Hypertension”